Stockwatch: Details Differ Between Pfizer And AstraZeneca's Second-Quarter Earnings Reports
As Analysts’ Low Expectations Continue To Beaten, Differences Remain In Big Pharma Earnings And Guidance
Executive Summary
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
You may also be interested in...
Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.